BioNTech präsentiert auf dem ESMO-Kongress 2024 klinische Daten-Updates aus dem mRNA und immunmodulatorischen Onkologie-Portfolio
September 05, 2024 07:15 ET
|
BioNTech SE
MAINZ, Deutschland, 05. September 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf dem diesjährigen Kongress der European Society for Molecular Oncology („ESMO“), der vom...
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
September 05, 2024 07:15 ET
|
BioNTech SE
MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the...
Hummingbird Bioscience Announces Key Leadership Appointments
July 29, 2024 08:00 ET
|
Hummingbird Bioscience
Hummingbird Bioscience Announces Key Leadership Appointments
• Kon Yew Kwek appointed Chief Medical Officer
• Lisa Ooi appointed Chief Operating Officer
BioNTech und DualityBio erhalten Fast-Track-Status der FDA für Antikörper-Wirkstoff-Konjugat-Kandidat BNT324/DB-1311 bei Prostatakrebs
June 24, 2024 06:45 ET
|
BioNTech SE
Der Status basiert auf präklinischen Daten und Daten aus einer laufenden Phase-1/2-Studie für BNT324/DB-1311; vorläufige klinische Phase-1/2-Daten zeigten eine Anti-Tumor-Aktivität und ein...
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
June 24, 2024 06:45 ET
|
BioNTech SE
Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2...
Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest Clinical Trial Data
June 21, 2024 17:30 ET
|
Novotech
BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of...
Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024
May 13, 2024 05:30 ET
|
Hummingbird Bioscience
Hummingbird Bioscience will present next-generation antibody-drug conjugate capabilities at PEGS Boston 2024 for the first time.
Antibody Therapeutics Market to Witness Remarkable Growth with a CAGR of 13% during the Forecast Period | MarketDigits
February 22, 2024 08:30 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 22, 2024 (GLOBE NEWSWIRE) -- According to MarketDigits, Antibody Therapeutics Market was valued USD 232 Billion in 2023 and projected to reach USD 535.8 Billion by 2030, growing at a...
BioNTech und DualityBio erhalten Fast-Track-Status der FDA für innovativen Antikörper-Wirkstoff-Konjugat-Kandidat BNT325/DB-1305
January 31, 2024 06:45 ET
|
BioNTech SE
Der Status basiert auf vorläufigen Daten zur Sicherheit und Wirksamkeit aus einer laufenden Phase-1/2-Studie in Patientinnen mit platinresistentem Epithelkarzinom der Eierstöcke, Eileiter...
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
January 31, 2024 06:45 ET
|
BioNTech SE
Designation is based on preliminary safety and efficacy data from an ongoing Phase 1/2 trial in patients with platinum-resistant ovarian epithelial cancer, fallopian tube, or primary...